Delbert Pharma

Since 2013, Delbert Pharma has been preserving the market availability of drugs considered critical to our healthcare system and repositioning some for new indications, notably in rare diseases. Our commitment, as defenders of the pharmaceutical heritage, is to maintain access to essential medications to ensure the continuity of treatments for all. To support their European development, Laboratoires DELBERT become DELBERT Pharma in March 2024. This page is not intended to report adverse events that may be related to the medications marketed by Delbert Pharma. For this, please contact your healthcare professional. Delbert Pharma constantly monitors the safety of its drugs and encourages you to report any side effects directly at +33 (0) 1 46 99 68 20 or pharmacovigilance@delbert.fr. #RevivingCriticalMedicines